Quality Control of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate《Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review》 was published in 2022. The authors were O Murchu, Eamon;Spillane, Susan;Byrne, Paula;O′Neill, Michelle;Harrington, Patricia;Ryan, Mairin, and the article was included in《Annals of Pharmacotherapy》. The author mentioned the following in the article:
A review. To conduct a systematic review on the effectiveness and safety of pharmacol. and nonpharmacol. interventions, in the ambulatory setting, aimed at preventing severe disease in patients with COVID-19. Electronic databases (PubMed, EMBASE, and EuropePMC) were searched on Jan. 6, 2021. Study Selection and Data Extraction:: A systematic review was conducted, adhering to PRISMA guidelines. The quality of individual trials was assessed using the Cochrane Risk-of-Bias Tool 2, and the certainty of evidence was assessed using GRADE. Data Synthesis:: The collective search retrieved 3818 citations. Eight trials relating to 9 pharmacol. interventions were identified. No evidence for nonpharmacol. interventions was identified. Low certainty evidence of effectiveness in preventing severe disease was found for fluvoxamine (absolute difference: -8.7%; 95% CI: -1.8% to -16.4%) and bamlanivimab plus etesevimab (absolute difference: -4.9%; 95% CI: -0.8% to -8.9%). Both trials were limited by small sample sizes and short durations of follow-up. In addition, very low certainty evidence of effect was found for ivermectin plus doxycycline and sulodexide. Based on published data, insufficient evidence of effect was found for bamlanivimab (monotherapy), casirivimab plus imdevimab, ivermectin (monotherapy), nitazoxanide, and peginterferon lambda. Relevance to Patient Care and Clin. Practice:: This review assessed all ambulatory treatments for COVID-19 that may improve patient outcomes and reduce hospitalizations. Recent trials have shown promising results for a number of pharmacol. agents to treat COVID-19 in the ambulatory setting. However, larger, more robust trials are needed to support the routine use of these agents outside of monitored clin. trials.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.
2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), an anthelmintic agent, exhibits a broad spectrum of activities against a wide variety of helminths, protozoa, and enteric bacteria infecting animals and humans.Quality Control of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate
Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica